PER® Chemotherapy Foundation Symposium (CFS) | Conference

Adjuvant Options Arrive for Melanoma

November 9th 2018

The treatment armamentarium for adjuvant melanoma has expanded rapidly, which has left the treatment challenge of selecting between immunotherapy and targeted therapy without any head-to-head comparative data.

Personalized Immunotherapy Combinations on Horizon

November 9th 2018

Future development of novel immunotherapy combinations should be based on individual patient characteristics, such as patient-level immune targets and tumor microenvironment.

Emerging Agents, Strategies Propel Progress in Follicular Lymphoma

November 8th 2018

Novel agents and treatment strategies continue to expand the armamentarium in follicular lymphoma, explains John P. Leonard, MD, in a session at the 36th Annual CFS®.

CAR T-Cell Therapies Moving to Outpatient Setting

November 8th 2018

The high durable response rates seen with CAR T-cell therapies have helped fill a high unmet need for patients with relapsed/refractory diffuse large B-cell lymphoma, with questions remaining on the optimal way to use these agents following the FDA approval of 2 therapies in the past year.

Novel Agents, Earlier Diagnosis Driving Survival Gains in CLL

November 8th 2018

The median overall survival for patients with chronic lymphocytic leukemia has more than tripled since the 1970s, primarily due to an ever-expanding armamentarium of novel agents and earlier diagnosis.

Dr. Markman on Endpoints in Clinical Trials for Ovarian Cancer

November 16th 2017

Maurie Markman, MD, president of medicine and science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses endpoints in clinical trials for ovarian cancer.

Dr. Bendell on the Future of Regorafenib for Patients With CRC

November 15th 2017

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the future of regorafenib (Stivarga) for patients with colorectal cancer (CRC).

Expert Discusses Treatment Options in Advanced CRC

November 13th 2017

Cathy Eng, MD, discusses optimizing sequencing beyond disease progression in CRC.

Comparing Abiraterone and Docetaxel in Prostate Cancer Treatment

November 11th 2017

Christopher Sweeney, MBBS, physician, Dana-Farber Cancer Institute, compares treatment with abiraterone verus docetaxel in patients with prostate cancer.

EGFR-Positive NSCLC Is Emerging as Model for Precision Medicine

November 11th 2017

It has been a “renaissance” in the non–small cell lung cancer landscape with the rapid evolution of targeted treatment for patients with EGFR-mutation–positive disease, says Edward S. Kim, MD.

Dr. Garon on Immunotherapy as Salvage Treatment for Advanced Lung Cancer

November 11th 2017

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses the possibility of administering PD1 or PD-L1 blockades as a third-line or salvage therapy for patients with advanced lung cancer.

Treating Advanced Non-Driver Lung Adenocarcinoma

November 11th 2017

The approach to first-line treatment of advanced non-small cell lung cancer (NSCLC) has been evolving rapidly, particularly with respect to patients with lung adenocarcinoma.

MSI-H Experience Delivers Another Exciting Breakthrough in Immuno-Oncology

November 10th 2017

Immunotherapy is being positioned as an earlier therapeutic option for patients with high levels of microsatellite instability or mismatch repair deficiency, regardless of their tumor location, expert says.

Dr. Finn on the Revolution of CDK4/6 Inhibition in HR+ Breast Cancer

November 10th 2017

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses the significant advances with CDK4/6 inhibitors in the field of hormone receptor (HR)-positive breast cancer.

PARPs Bring Excitement to Ovarian Treatment

November 10th 2017

PARP inhibitors offer exciting opportunities to improve outcomes for patients with ovarian cancer and hopefully will be moved to the front-line setting if the evidence warrants it, said Susana M. Campos, MD.

Dr. Eng on Roles of Regorafenib and TAS-102 in CRC Treatment

November 10th 2017

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ongoing roles of regorafenib (Stivarga) and TAS-102 (Lonsurf) in colorectal cancer (CRC) treatment.

How Reliable Is PD-L1 Expression as a Predictor of Immune Response?

November 9th 2017

There is a great need—and opportunity—to improve ovarian cancer outcomes by understanding the immune milieu of ovarian cancers and harnessing the power of immunotherapy.

Endometrial Cancer Enters Immunotherapy Age

November 9th 2017

The tumor-site agnostic FDA approval of the PD-1 inhibitor pembrolizumab (Keytruda) for patients with microsatellite instability-high or mismatch repair deficient solid tumors has helped propel endometrial cancer into the immunotherapy age.

Dr. Abou-Alfa on the Ongoing Impact and Role of Regorafenib in HCC

November 9th 2017

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the ongoing role and impact of regorafenib (Stivarga) in the paradigm of hepatocellular carcinoma (HCC) in an interview during the 2017 Chemotherapy Foundation Symposium.

Refining Role of Brentuximab Vedotin and Immunotherapy in Hodgkin Lymphoma

November 9th 2017

As clinicians’ understanding of the disease pathobiology associated with Hodgkin lymphoma (HL) has increased, novel treatments have emerged.